US 11,918,686 B2
Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
Andre E. Nel, Sherman Oaks, CA (US); Jeffrey I. Zink, Sherman Oaks, CA (US); and Huan Meng, Los Angeles, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Sep. 21, 2020, as Appl. No. 16/948,498.
Application 16/948,498 is a continuation of application No. 14/772,740, granted, now 10,828,255, previously published as PCT/US2014/020857, filed on Mar. 5, 2014.
Claims priority of provisional application 61/858,388, filed on Jul. 25, 2013.
Claims priority of provisional application 61/773,013, filed on Mar. 5, 2013.
Prior Publication US 2021/0077397 A1, Mar. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 31/337 (2006.01); A61K 31/4709 (2006.01); A61K 31/7068 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61P 35/00 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 9/5115 (2013.01); A61K 31/337 (2013.01); A61K 31/4709 (2013.01); A61K 31/7068 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01)] 20 Claims
 
1. A drug delivery carrier comprising:
a silica body having a plurality of pores suitable to receive a therapeutic agent therein, and having a surface;
an intact lipid bilayer coating the surface and encapsulating the silica body and stably sealing the plurality of pores, wherein the encapsulating is performed without lipid phase exchange and without contacting a preformed liposome with the silica body;
a first therapeutic agent within the pores of the silica body, wherein the first therapeutic agent comprises gemcitabine; and
a second therapeutic agent disposed in the lipid bilayer, wherein the second therapeutic agent comprises paclitaxel.